Dosing

2 Weeks
On
2 Weeks
Off
2 Weeks
On

ZYCLARA is the only imiquimod cream available in a metered-dose pump, for consistent dosing, every time.1

Only 1.3% of ZYCLARA 3.75%-treated patients discontinued due to adverse events1

Local skin reactions in the treatment area

ALL GRADESa (%)

SEVERE (%)

ZYCLARA CREAM, 3.75%

(N=160)

PLACEBO

(N=159)

Erythema

Severe Erythema

96

25

78

0

Scabbing/Crusting

Severe Scabbing/Crusting

94

14

45

0

Edema

Severe Edema

75

6

19

0

Erosion/Ulceration

Severe Erosion/Ulceration

62

11

9

0

Exudate

Severe Exudate

51

6

4

0

Flaking/Scaling/Dryness

Severe Flaking/Scaling/Dryness

91

8

77

1

* All Grades: mild, moderate, or severe.

In clinical studies for actinic keratosis, the most common adverse events involved skin reactions in the application area including erythema, scabbing/crusting, flaking/scaling/dryness, edema, erosion/ulceration, and exudate. Most local skin reactions were rated as mild to moderate. Overall, in clinical trials, 11% (17/160) of subjects in the 3.75% arm and 0% of the placebo cream arm required rest periods due to local adverse skin reactions.



Value Savings for your Patients

Get details

Patient Tools

*This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for other terms and conditions that apply.

INDICATION

ZYCLARA (imiquimod) Cream 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults.

IMPORTANT SAFETY INFORMATION FOR ZYCLARA CREAM

Please click here for Prescribing Information, including Patient Information.

References: 1. ZYCLARA Cream Package Insert.Scottsdale, AZ: Medicis, the Dermatology Company; February 2012. 2. Data on file. Valeant Pharmaceuticals International Inc. 3. Jorizzo JL, Markowitz O,Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9(9):1101–1108.